MDT

84.84

+1.12%↑

VEEV

231.97

+2.7%↑

A

107.68

+1.21%↑

WBA

10.94

-0.18%↓

CHE

579.74

+3.38%↑

MDT

84.84

+1.12%↑

VEEV

231.97

+2.7%↑

A

107.68

+1.21%↑

WBA

10.94

-0.18%↓

CHE

579.74

+3.38%↑

MDT

84.84

+1.12%↑

VEEV

231.97

+2.7%↑

A

107.68

+1.21%↑

WBA

10.94

-0.18%↓

CHE

579.74

+3.38%↑

MDT

84.84

+1.12%↑

VEEV

231.97

+2.7%↑

A

107.68

+1.21%↑

WBA

10.94

-0.18%↓

CHE

579.74

+3.38%↑

MDT

84.84

+1.12%↑

VEEV

231.97

+2.7%↑

A

107.68

+1.21%↑

WBA

10.94

-0.18%↓

CHE

579.74

+3.38%↑

Search

SpringWorks Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

46.23 0.17

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

46.11

Max

46.24

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-24M

-77M

Pardavimai

12M

62M

Pelnas, tenkantis vienai akcijai

-1.04

Pelno marža

-125.586

Darbuotojai

368

EBITDA

-23M

-80M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+34.54% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1B

3.1B

Ankstesnė atidarymo kaina

46.06

Ankstesnė uždarymo kaina

46.23

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

SpringWorks Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-28 11:25; UTC

Įsigijimai, susijungimai, perėmimai

Germany's Merck to Buy SpringWorks for $3.9 Billion -- Update

2025-04-28 06:41; UTC

Įsigijimai, susijungimai, perėmimai

Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal

2025-02-11 07:03; UTC

Įsigijimai, susijungimai, perėmimai

Germany's Merck in Talks to Buy SpringWorks Therapeutics

2025-02-10 16:38; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

2025-04-28 15:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Merck KGaA's $3.9B SpringWorks Therapeutics Buy Underwhelms -- Market Talk

2025-04-28 09:20; UTC

Karštos akcijos

Stocks to Watch Monday: DoorDash, Merck, Spirit AeroSystems, Airbus -- WSJ

2025-04-28 06:06; UTC

Įsigijimai, susijungimai, perėmimai

Germany's Merck: Acquisition Will Strengthen Merck Healthcare Presence in U.S.

2025-04-28 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Germany's Merck: Planned Acquisition Will Immediately Add Revenue, Accelerate Growth

2025-04-28 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Germany's Merck: Deal Is for Purchase Price of $47 a Share in Cash

2025-04-28 06:04; UTC

Įsigijimai, susijungimai, perėmimai

Germany's Merck to Buy SpringWorks for About $3.9B

2025-04-28 06:02; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Germany's Merck to Buy SpringWorks Therapeutics

2025-04-24 22:51; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025-04-24 20:54; UTC

Įsigijimai, susijungimai, perėmimai

Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into

2025-04-24 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share

2025-04-24 19:05; UTC

Įsigijimai, susijungimai, perėmimai

Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ

2025-04-24 19:05; UTC

Įsigijimai, susijungimai, perėmimai

Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ

2025-04-24 19:05; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ

2025-04-24 19:05; UTC

Įsigijimai, susijungimai, perėmimai

Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ

2025-02-11 10:54; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

2025-02-11 10:52; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Akcijų palyginimas

Kainos pokytis

SpringWorks Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

34.54% į viršų

12 mėnesių prognozė

Vidutinis 62.13 USD  34.54%

Aukščiausias 84 USD

Žemiausias 47 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines SpringWorks Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

4

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

37.9899 / 46.21Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.